Avidity Biosciences Inc., a wholly owned subsidiary of Novartis, is developing novel RNA therapeutics. Its platform enables targeted RNA delivery by combining antibody specificity with oligonucleotide precision, addressing disease mechanisms at their source. This approach allows access to tissues previously unreachable by other RNA therapies, advancing precision medicine across rare therapeutic areas
